RT Journal Article
SR Electronic
T1 Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21268308
DO 10.1101/2021.12.30.21268308
A1 Faustini, Sian E
A1 Shields, Adrian M
A1 Banham, Gemma
A1 Wall, Nadezhda
A1 Al-Taei, Saly
A1 Tanner, Chloe
A1 Ahmed, Zahra
A1 Efstathiou, Elena
A1 Townsend, Neal
A1 Plant, Tim
A1 Perez-Toledo, Marisol
A1 Jasiulewicz, Aleksandra
A1 Price, Ruth
A1 McLaughlin, James
A1 Farnan, John
A1 Moore, Julie
A1 Robertson, Louise
A1 Nesbit, Andrew
A1 Curry, Grace
A1 Black, Amy
A1 Cunningham, Adam F
A1 Harper, Lorraine
A1 Moore, Tara
A1 Drayson, Mark T
A1 Richter, Alex G
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21268308.abstract
AB Variants of SARS-CoV-2 may evade natural and vaccine induced immunity and monoclonal antibody immunotherapeutics. There is an urgent need to know how well antibodies, induced by healthy and Clinically Extremely Vulnerable (CEV) patients, will bind and thus help reduce transmission and severity of infection from variants of concern (VOC). This study determines the cross-reactive binding of serum antibodies obtained prior to and 28 days after a third vaccination in three cohorts; a health care worker cohort who received three doses of Pfizer-BioNtech (PPP), a cohort of CEV patients received two doses of the AstraZeneca-ChAdOx1-nCoV-19 (AAP) vaccine, followed by a third PFZ vaccine and a haemodialysis cohort that had a mixture of two AZ or PFZ vaccines followed by a PFZ booster. Six months post second vaccine there was evidence of antibody waning with 58.9% of individuals in the HD cohort seropositive against Wuhan, 34.4% Delta and 62.2% Omicron strains. For the AAP cohort, equivalent figures were 62.5%, 45.8% and 91.7% and the PPP cohort 92.2%, 90% and 91.1%. Post third dose vaccination there were universal increases in seropositivity and median optical density. For the HD cohort, 98.8% were seropositive to the Wuhan strain, 97.6% against Delta and 100% against Omicron strains. For the PPP and AAP cohorts, 100% were seropositive against all 3 strains. Lastly, we examined the WHO NIBSC 20/136 standard and there was no loss of antibody binding to either VOC. Similarly, a dilution series of Sotrovimab (GSK) found this therapeutic monoclonal antibody bound similarly to all VOC.HighlightsIgG anti-SARS-CoV-2 Omicron spike glycoprotein antibody levels were high in 100% of health care workers (HCW), a general practice population considered clinically extremely vulnerable (CEV) and haemodialysis patients (HD) 4 weeks after a third SARS-CoV-2 vaccine dose (Pfizer-BioNtech-PFZ).For both Delta and Omicron variant spike glycoproteins these antibody levels were highest in the CEV cohort who had previously received two doses of AstraZeneca ChAdOx1 nCoV-19 vaccine (AAP), lower in HCW who had previously received two doses of PFZ (PPP) and lowest in HD who had a mix of vaccines for the first and second dosePrior to this third vaccine dose and 6 months post second vaccine dose there was evidence of significant waning of antibodies against VOC.Competing Interest StatementMark Drayson and Tim Plant have shares in Abingdon HealthFunding StatementThe COCO/PITCH healthcare worker cohort was funded by the United Kingdom Department of Health and Social Care and United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call as part of the PITCH Consortium. The HD cohort was funded by the United Kingdom Research and Innovation COVID-19 Rapid Response Rolling Call.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COCO study was ethically approved for this work by the London - Camden and Kings Cross Research Ethics Committee on behalf of the United Kingdom Health Research Authority - reference 20/HRA/1817. The Haemodialysis study was ethically approved for this work by the North West-Preston Research Committee on behalf of the United Kingdom Health Research Authority for the National Institute of Health Research Coronavirus Immunological Analysis study - reference 20/NW/0240. The Ulster study was ethically approved for this work by the Office of Research Ethics Committee for Northern Ireland on behalf of the United Kingdom Health Research Authority - reference 20/WM/0184. The pre-2019 health controls was ethically approved for this work by the University of Birmingham Research Ethics Committee, United Kingdom - reference ERN_16-178 (2002/201, Amendment Number 4)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors